Skip to content

Jazz Pharmaceuticals plc

JAZZ

CIK 0001232524

← back to feed
Revenue (TTM)
$4.14B
+4.9% YoY Q1 Apr 2026
Net Income (TTM)
−$266.5M
−163.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$4.75
−167.5% YoY Q1 Apr 2026
Gross Margin
14.8%
Q1 Apr 2026
Operating Margin
-8.4%
Q1 Apr 2026
Net Margin
-6.4%
Q1 Apr 2026
Free Cash Flow (TTM)
$1.38B
Q1 Apr 2026
Cash
$1.84B
Q1 Apr 2026
Total Debt
$5.35B
Q1 Apr 2026
Shares Outstanding
62.74M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings